Q32 Bio Inc. (QTTB)

↓ Download CSV

CIK 0001661998 · Nasdaq · Pharmaceutical Preparations

  • Sector Manufacturing
  • Incorporated DE
  • Fiscal year ends Dec 31

In fiscal 2025, Q32 Bio Inc. reported revenue of $53.74M. The company was profitable, with a net margin of 55.5%. It held $61.78M in total assets against $19.76M in total liabilities.

Key ratios (FY2025)

31.5%
Operating margin
55.5%
Net margin
71.0%
Return on equity
Metric (FY)2025202420232022202120202019201820172016
Revenue$53.74M$0-$6.65M$3.68M
Operating Income$16.90M-$66.10M-$48.26M-$133.28M-$95.95M-$130.26M-$109.94M-$59.93M-$29.66M
Net Income$29.82M-$47.73M-$53.74M-$5.00M-$95.76M-$128.69M-$103.92M-$55.58M-$29.99M
EPS (Diluted)$2.42$-6.58$-153.96$-0.09$-1.73
Total Assets$61.78M$92.33M$47.06M$228.47M$211.72M$263.74M$310.57M$259.09M$137.53M
Total Liabilities$19.76M$86.66M$118.53M$50.49M$42.07M$67.74M$52.06M$62.74M$39.22M
Shareholders' Equity$42.01M$5.67M-$182.92M-$130.71M$169.65M$196.00M$258.51M$196.35M-$39.45M-$9.89M
Cash & Equivalents$48.30M$77.97M$25.62M$33.99M$108.38M$217.43M$53.77M$38.22M$51.58M$11.39M
Operating Cash Flow-$33.54M-$67.72M-$18.68M-$113.66M-$109.75M-$94.33M-$91.36M-$42.56M$6.48M
Capital Expenditures$0$75.0K$5.0K$1.28M$2.40M$3.73M$21.83M$24.94M$1.96M
Shares Outstanding12.86M12.20M359.6K57.48M57.15M50.27M45.12M37.36M2.64M